The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients
Date
2020-10Journal
Diabetes CarePublisher
American Diabetes AssociationType
ArticleOther
Metadata
Show full item recordIdentifier to cite or link to this item
http://hdl.handle.net/10713/13808ae974a485f413a2113503eed53cd6c53
10.2337/dci20-0039
Scopus Count
Collections
Related articles
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
- Authors: Kabadi UM
- Issue date: 2021 Jan
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
- Authors: Tsapas A, Karagiannis T, Avgerinos I, Matthews DR, Bekiari E
- Issue date: 2021 Jan
- In type 2 diabetes, some glucose-lowering drugs reduce HbA<sub>1c</sub> more than others; drugs do not differ for mortality.
- Authors: Gandhi GY
- Issue date: 2020 Nov 17
- Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
- Authors: Schernthaner G
- Issue date: 2021 May
- Positioning newer drugs in the management of type 2 diabetes.
- Authors: Marx N, Davies MJ, Grant PJ, Mathieu C, Petrie JR, Cosentino F, Buse JB
- Issue date: 2021 Mar